Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash

Adam M. Huber, Susan Kim, Ann M. Reed, Ruy Carrasco, Brian M. Feldman, Sandy D. Hong, Philip Kahn, Homaira Rahimi, Angela Byun Robinson, Richard K. Vehe, Jennifer E. Weiss, Charles Spencer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective. Juvenile dermatomyositis (JDM) is the most common form of idiopathic inflammatory myopathy in children. While outcomes are generally thought to be good, persistence of skin rash is a common problem. The goal of this study was to describe the development of clinical treatment plans (CTP) for children with JDM characterized by persistent skin rash despite complete resolution of muscle involvement. Methods. The Childhood Arthritis and Rheumatology Research Alliance, a North American consortium of pediatric rheumatologists and other healthcare providers, used a combination of Delphi surveys and nominal group consensus meetings to develop CTP that reflected consensus on typical treatments for patients with JDM with persistent skin rash. Results. Consensus was reached on patient characteristics and outcome assessment. Patients should have previously received corticosteroids and methotrexate (MTX). Three consensus treatment plans were developed. Plan A added intravenous immunoglobulin (IVIG) if it was not already being used. Plan B added mycophenolate mofetil, while Plan C added cyclosporine. Continuation of previous treatments, including corticosteroids, MTX, and IVIG, was permitted in plans B and C. Conclusion. Three consensus CTP were developed for use in children with JDM and persistent skin rash despite complete resolution of muscle disease. These CTP reflect typical treatment approaches and are not to be considered treatment recommendations or standard of care. Using prospective data collection and statistical methods to account for nonrandom treatment assignment, it is expected that these CTP will be used to allow treatment comparisons, and ultimately determine the best treatment for these patients.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalJournal of Rheumatology
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Rheumatology
Exanthema
Arthritis
Consensus
Research
Therapeutics
Levonorgestrel
Intravenous Immunoglobulins
Methotrexate
Juvenile dermatomyositis
Adrenal Cortex Hormones
Patient Outcome Assessment
Mycophenolic Acid
Muscles
Myositis
Group Processes
Standard of Care
Health Personnel
Cyclosporine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. / Huber, Adam M.; Kim, Susan; Reed, Ann M.; Carrasco, Ruy; Feldman, Brian M.; Hong, Sandy D.; Kahn, Philip; Rahimi, Homaira; Robinson, Angela Byun; Vehe, Richard K.; Weiss, Jennifer E.; Spencer, Charles.

In: Journal of Rheumatology, Vol. 44, No. 1, 01.01.2017, p. 110-116.

Research output: Contribution to journalArticle

Huber, AM, Kim, S, Reed, AM, Carrasco, R, Feldman, BM, Hong, SD, Kahn, P, Rahimi, H, Robinson, AB, Vehe, RK, Weiss, JE & Spencer, C 2017, 'Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash', Journal of Rheumatology, vol. 44, no. 1, pp. 110-116. https://doi.org/10.3899/jrheum.160688
Huber, Adam M. ; Kim, Susan ; Reed, Ann M. ; Carrasco, Ruy ; Feldman, Brian M. ; Hong, Sandy D. ; Kahn, Philip ; Rahimi, Homaira ; Robinson, Angela Byun ; Vehe, Richard K. ; Weiss, Jennifer E. ; Spencer, Charles. / Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. In: Journal of Rheumatology. 2017 ; Vol. 44, No. 1. pp. 110-116.
@article{b732ba3f4fcd4449af6109ef234d65f6,
title = "Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash",
abstract = "Objective. Juvenile dermatomyositis (JDM) is the most common form of idiopathic inflammatory myopathy in children. While outcomes are generally thought to be good, persistence of skin rash is a common problem. The goal of this study was to describe the development of clinical treatment plans (CTP) for children with JDM characterized by persistent skin rash despite complete resolution of muscle involvement. Methods. The Childhood Arthritis and Rheumatology Research Alliance, a North American consortium of pediatric rheumatologists and other healthcare providers, used a combination of Delphi surveys and nominal group consensus meetings to develop CTP that reflected consensus on typical treatments for patients with JDM with persistent skin rash. Results. Consensus was reached on patient characteristics and outcome assessment. Patients should have previously received corticosteroids and methotrexate (MTX). Three consensus treatment plans were developed. Plan A added intravenous immunoglobulin (IVIG) if it was not already being used. Plan B added mycophenolate mofetil, while Plan C added cyclosporine. Continuation of previous treatments, including corticosteroids, MTX, and IVIG, was permitted in plans B and C. Conclusion. Three consensus CTP were developed for use in children with JDM and persistent skin rash despite complete resolution of muscle disease. These CTP reflect typical treatment approaches and are not to be considered treatment recommendations or standard of care. Using prospective data collection and statistical methods to account for nonrandom treatment assignment, it is expected that these CTP will be used to allow treatment comparisons, and ultimately determine the best treatment for these patients.",
author = "Huber, {Adam M.} and Susan Kim and Reed, {Ann M.} and Ruy Carrasco and Feldman, {Brian M.} and Hong, {Sandy D.} and Philip Kahn and Homaira Rahimi and Robinson, {Angela Byun} and Vehe, {Richard K.} and Weiss, {Jennifer E.} and Charles Spencer",
year = "2017",
month = "1",
day = "1",
doi = "10.3899/jrheum.160688",
language = "English (US)",
volume = "44",
pages = "110--116",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "1",

}

TY - JOUR

T1 - Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash

AU - Huber, Adam M.

AU - Kim, Susan

AU - Reed, Ann M.

AU - Carrasco, Ruy

AU - Feldman, Brian M.

AU - Hong, Sandy D.

AU - Kahn, Philip

AU - Rahimi, Homaira

AU - Robinson, Angela Byun

AU - Vehe, Richard K.

AU - Weiss, Jennifer E.

AU - Spencer, Charles

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective. Juvenile dermatomyositis (JDM) is the most common form of idiopathic inflammatory myopathy in children. While outcomes are generally thought to be good, persistence of skin rash is a common problem. The goal of this study was to describe the development of clinical treatment plans (CTP) for children with JDM characterized by persistent skin rash despite complete resolution of muscle involvement. Methods. The Childhood Arthritis and Rheumatology Research Alliance, a North American consortium of pediatric rheumatologists and other healthcare providers, used a combination of Delphi surveys and nominal group consensus meetings to develop CTP that reflected consensus on typical treatments for patients with JDM with persistent skin rash. Results. Consensus was reached on patient characteristics and outcome assessment. Patients should have previously received corticosteroids and methotrexate (MTX). Three consensus treatment plans were developed. Plan A added intravenous immunoglobulin (IVIG) if it was not already being used. Plan B added mycophenolate mofetil, while Plan C added cyclosporine. Continuation of previous treatments, including corticosteroids, MTX, and IVIG, was permitted in plans B and C. Conclusion. Three consensus CTP were developed for use in children with JDM and persistent skin rash despite complete resolution of muscle disease. These CTP reflect typical treatment approaches and are not to be considered treatment recommendations or standard of care. Using prospective data collection and statistical methods to account for nonrandom treatment assignment, it is expected that these CTP will be used to allow treatment comparisons, and ultimately determine the best treatment for these patients.

AB - Objective. Juvenile dermatomyositis (JDM) is the most common form of idiopathic inflammatory myopathy in children. While outcomes are generally thought to be good, persistence of skin rash is a common problem. The goal of this study was to describe the development of clinical treatment plans (CTP) for children with JDM characterized by persistent skin rash despite complete resolution of muscle involvement. Methods. The Childhood Arthritis and Rheumatology Research Alliance, a North American consortium of pediatric rheumatologists and other healthcare providers, used a combination of Delphi surveys and nominal group consensus meetings to develop CTP that reflected consensus on typical treatments for patients with JDM with persistent skin rash. Results. Consensus was reached on patient characteristics and outcome assessment. Patients should have previously received corticosteroids and methotrexate (MTX). Three consensus treatment plans were developed. Plan A added intravenous immunoglobulin (IVIG) if it was not already being used. Plan B added mycophenolate mofetil, while Plan C added cyclosporine. Continuation of previous treatments, including corticosteroids, MTX, and IVIG, was permitted in plans B and C. Conclusion. Three consensus CTP were developed for use in children with JDM and persistent skin rash despite complete resolution of muscle disease. These CTP reflect typical treatment approaches and are not to be considered treatment recommendations or standard of care. Using prospective data collection and statistical methods to account for nonrandom treatment assignment, it is expected that these CTP will be used to allow treatment comparisons, and ultimately determine the best treatment for these patients.

UR - http://www.scopus.com/inward/record.url?scp=85008147292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008147292&partnerID=8YFLogxK

U2 - 10.3899/jrheum.160688

DO - 10.3899/jrheum.160688

M3 - Article

VL - 44

SP - 110

EP - 116

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 1

ER -